Tenax Therapeutics, Inc. (TENX)
NASDAQ: TENX · Real-Time Price · USD
9.65
+0.30 (3.21%)
At close: Dec 5, 2025, 4:00 PM EST
10.00
+0.35 (3.63%)
After-hours: Dec 5, 2025, 7:54 PM EST
Tenax Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
6
Market Cap
391.50M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
TENX News
- 11 days ago - Tenax Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 22 days ago - Tenax Therapeutics, Inc. (TENX) Discusses Scientific Rationale and Development Strategy for TNX-103 in PH-HFpEF Transcript - Seeking Alpha
- 23 days ago - Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF - GlobeNewsWire
- 4 weeks ago - Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - GlobeNewsWire
- 2 months ago - Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF - GlobeNewsWire
- 3 months ago - Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025 - GlobeNewsWire
- 4 months ago - Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire